

# The 1st International Electronic Conference on Medicinal Chemistry and Pharmaceutics



01-30 November 2025 | Online


## THREE-DIMENSIONAL SHAPE SIMILARITY APPROACH FOR THE DISCOVERY OF **IL-1R1 RECEPTOR INHIBITORS**

Minh Nhat Le,<sup>1</sup> Nhu Huynh Tam Mai,<sup>2</sup> Nhi Thi Hanh Nguyen,<sup>2</sup> Tan Thanh Mai<sup>1,\*</sup> <sup>1</sup>University of Medicine and Pharmacy at Ho Chi Minh City – School of Pharmacy


## INTRODUCTION & AIM

Interleukin-1β (IL-1β) is a prototypical cytokine of the IL-1 family that regulates innate and adaptive immunity. Its cognate receptor, interleukin-1 receptor type 1 (IL-1R1), is therefore a tractable target for anti-inflammatory drug discovery. The peptide antagonist AF10847 binds IL-1R1 and disrupts the IL-1β/IL-1R1 protein—protein interface, validating the receptor's druggability. However, its peptidic nature entails poor oral bioavailability and unfavorable developability. This study aimed to discover non-peptidic small molecules capable of inhibiting IL-1R1 using a 3D shape-similarity strategy anchored on AF10847. The IL-1R1/AF10847 co-crystal structure was prepared for modeling, and the binding pocket was delineated using FPocket, DoGSiteScorer, and DeepSite. In silico alanine scanning of the complex identified interaction "hot spots" at the protein-protein interface. Following comprehensive conformer enumeration of AF10847, a ROCS query capturing its molecular envelope and salient pharmacophoric features was constructed and deployed to virtually screen large purchasable libraries (Enamine, ChemDiv, Asinex and NCI Open Database). Candidates were ranked by Tanimoto similarity score and lightly filtered for drug-likeness prior to structure-based triage. Top-ranked molecules underwent ensemble molecular docking into multiple IL-1R1 conformations to accommodate receptor flexibility, with poses assessed by consensus scoring and interaction-fingerprint analysis for consistency with the AF10847 recognition pattern. Short all-atom molecular-dynamics simulations were then performed to evaluate pose stability via heavy-atom RMSD and hydrogen-bond occupancy and to obtain qualitative affinity estimates using trajectory-averaged metrics. This computational cascade identified several chemically diverse small-molecule candidates predicted to engage IL-1R1 in persistent, well-packed poses with favorable interaction networks. These in silico hits constitute tractable starting points for experimental validation, including biochemical binding assays and cellular readouts of IL-1β signaling, orthogonal selectivity counterscreens early ADMET profiling to guide medicinal-chemistry optimization toward orally available IL-1R1 modulators.

## METHOD




## LIGAND-BIDING SITE PREDICTION



## **MOLPROBITY CLEANFH-RAMA**

98.5% of all residues

were in allowed



96.0% of all residues

were in allowed

## **BUDE ALANINE SCAN**

Constellation	Constellation ΔΔG (kJ/mol)	Summed Individua I $\Delta\Delta$ Gs (kJ/mol)	Cooperativity (kJ/mol)
I12_I13_I6	69.8	61.6	8.1
I13_I15_I6	67.6	61.8	5.8
l13_l4_l6	67.4	57	10.4
I12_I13_I15	66	46.4	19.6
l12_l13_l4	65.8	41.6	24.2

Chain	Residue	Amino acid	ΔΔG (kJ/mol)	Std Dev
1	6	TRP	27.5	0
- 1	13	TYR	22.1	0
1	17	TYR	12.7	0
- 1	15	GLN	12.3	0
1	12	TYR	12.1	0

96.0% of all residues


were in allowed

## **RESULTS & DISCUSSION**


#### **ROCS SCREEN**

Database	Result	
Chemdiv	38	
NCI	9823	
Asinex	365	
Enamine	620	

#### AF10847 PEPTIDE-IL-1R1 CO-CRYSTAL **STRUCTURE**




#### **DOCKING PARAMETER**




**Scoring function: Vina Exhaustiveness: 8 Spacing: 0.375** Search box size:  $size_x = 44$ 

 $size_y = 52$  $size_z = 54$ Search box center:  $center_x = 24.832$ center\_y = 9.696  $center_z = 147.886$ 




**Distribution of Docking Scores** 

## **TOP DOCKING SCORES**



## **ADMET PREDICTION**



## CONCLUSION

Compounds with the highest overall Tanimoto similarity scores were selected to evaluate IL-1R1 binding via molecular docking and molecular dynamics simulations. Using these computational approaches, several small molecules predicted to bind IL-1R1 in silico were identified and can be advanced to in vitro testing.

## REFERENCES

- (1) Vigers GP et al. X-ray crystal structure of a small antagonist peptide bound to interleukin-1 receptor type 1. J Biol Chem. 2000;275(47):36927-36933.
- (2) Lee JY et al. Identification of new IL-7Rα small-molecule agonists: a multicomputational approach. SAR QSAR Environ Res. 2021;32(9):719-729.

## **ACKNOWLEDGEMENT**

This research was funded by the University of Medicine and Pharmacy at Ho Chi Minh City under contract number 223/2025/HĐ-ĐHYD, dated 28/04/2025. We are grateful to OpenEye, Cadence Molecular Sciences for the OpenEye Applications license, which greatly supported our research efforts.